Business, energy, technology, markets and global industry news from Business News Today

Greenstone Biosciences

PharmaDeviceNews Greenstone Biosciences
Greenstone Biosciences is advancing patient-derived cardiac cell research to identify potential therapies targeting cardiac fibrosis and cardiomyopathy in Duchenne muscular dystrophy following an NIH R61 grant. Representative image.
Pharma & Biotech

Can Greenstone Biosciences turn patient-derived heart cells into a Duchenne cardiomyopathy drug?

Greenstone Biosciences secured an NIH R61 grant to discover cardiac fibrosis drugs for Duchenne muscular dystrophy using iPSC and AI models.

Read More
Representative image: Scientists use human cell models, organoid research and artificial intelligence tools as the Greenstone Biosciences and Intel collaboration seeks to scale human-centric drug discovery and improve early drug safety prediction.
Medical Devices & Diagnostics

Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models

Discover how Greenstone Biosciences and Intel plan to scale iPSC drug discovery, and why validation will determine the platform’s impact.

Read More